Ascorbyl gamolenate

Drug Profile

Ascorbyl gamolenate

Alternative Names: Ascorbyl-gamma-linolenic acid; Ascorbyl-GLA; SC 103a

Latest Information Update: 22 Jan 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scotia Holdings [CEASED]
  • Class
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 22 Jan 2002 Discontinued-I for Diabetic neuropathies in United Kingdom (PO)
  • 19 Nov 1999 Phase-I clinical trials for Diabetic neuropathies in United Kingdom (PO)
  • 20 May 1999 SC 103 is now called Ascorbyl gamolenate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top